Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology and Kyowa Kirin announced positive interim data from the Phase 1a portion of KOMET-007 trial, evaluating ziftomenib in combination with standard treatments for acute myeloid leukemia (AML). The study showed impressive results with a 100% complete remission rate in NPM1-m and 83% in KMT2A-r first-line adverse risk AML patients when combined with 7+3 therapy.
Key highlights include 100% survival rate in first-line NPM1-m and 96% in KMT2A-r AML patients, with median follow-up of 31 and 19 weeks respectively. The drug demonstrated promising activity in relapsed/refractory cases with venetoclax/azacitidine combination. Ziftomenib was well-tolerated across all dose levels, with manageable side effects.
Based on these positive results, the companies plan to initiate KOMET-017, a global Phase 3 study, in mid-2025.
Kura Oncology (NASDAQ: KURA) has announced a virtual investor event scheduled for December 9, 2024, at 8:00 a.m. ET / 5:00 a.m. PT. The event will discuss updated clinical data from the KOMET-007 combination trial of ziftomenib, their oral and selective menin inhibitor, following its presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego.
The event will feature management team members and KOMET-007 trial investigators. Participants can join via phone (domestic: 800-715-9871, international: 646-307-1963, conference ID: 4326549) or through a live webcast available on Kura's website.
Kura Oncology (NASDAQ: KURA) announced its upcoming participation in the JMP Securities Hematology and Oncology Summit. Troy Wilson, President and Chief Executive Officer, will participate in a virtual fireside chat on December 2, 2024, at 2:00 p.m. ET / 11:00 a.m. PT. The event will be accessible via live audio webcast through the Investors section of Kura's website, with a replay available after the event.
Kura Oncology and Kyowa Kirin have announced a global strategic collaboration for developing and commercializing ziftomenib, a selective oral menin inhibitor for acute leukemias. The deal includes a $330 million upfront payment to Kura and potential milestone payments totaling $1.2 billion. The companies will share 50/50 profits in the U.S., with Kura leading U.S. operations and Kyowa Kirin having exclusive rights outside the U.S. The collaboration aims to advance ziftomenib through various development stages, including frontline indications and combinations. Kura expects to submit a New Drug Application in 2025 and initiate Phase 3 frontline studies in AML patients.
Kura Oncology and Kyowa Kirin have announced a global strategic collaboration for developing and commercializing ziftomenib, a selective oral menin inhibitor for acute myeloid leukemia (AML) treatment. Kura will receive a $330 million upfront payment and up to $1.2 billion in milestone payments. The companies will share 50/50 profits in the U.S., with Kura leading U.S. operations and Kyowa Kirin having exclusive rights outside the U.S. The collaboration includes development for frontline indications and combination therapies. Kura expects to submit a New Drug Application in 2025 and estimates a U.S. market opportunity of up to $3 billion annually in the frontline setting.
Kura Oncology has released its Q3 2024 financial results and corporate updates. Key highlights include the expected topline results from the registration-directed trial of ziftomenib in R/R NPM1-mutant AML in early 2025. Additionally, data from 100 patients in the Phase 1a study of ziftomenib will be presented at the ASH Annual Meeting. The Phase 1b expansion study of ziftomenib is now enrolling at 600 mg across all cohorts. Preclinical data supports the potential of ziftomenib in GIST, with a proof-of-concept study expected in 1H 2025. The first patient has been dosed in the study of KO-2806 and adagrasib in KRASG12C-mutated NSCLC. Financially, Kura reported a net loss of $54.4 million for Q3 2024, compared to $38.6 million in Q3 2023. R&D expenses rose to $41.7 million from $29.3 million, and G&A expenses increased to $18.2 million from $13.1 million. The company holds $455.3 million in cash, cash equivalents, and investments, expected to fund operations into 2027.
Kura Oncology (KURA) announced two abstracts from the KOMET-007 combination trial of ziftomenib will be presented at the ASH Annual Meeting in San Diego (December 7-10, 2024). The trial combines ziftomenib with standard treatments in NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) patients.
Key highlights include: All four Phase 1a dose-escalation cohorts advanced to Phase 1b expansion at 600 mg; 100% of NPM1-m AML patients and 84% of KMT2A-r patients remained on study; No DLTs or ziftomenib-induced QTc prolongation reported. The data suggests promising safety profile and robust activity in combination with standard treatments.
Kura Oncology (Nasdaq: KURA) announced it will release its third quarter 2024 financial results after U.S. market close on Thursday, November 7, 2024. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day, featuring management's discussion of financial results and a corporate update. Investors can access the call via phone or watch the webcast through the company's website.
Cartography Biosciences has appointed Troy E. Wilson, Ph.D., J.D. as an independent director to its Board of Directors. Wilson, a 25-year biopharma industry veteran, is currently President, CEO, and co-founder of Kura Oncology (NASDAQ: KURA). He brings extensive experience in founding and leading biotech companies, including Avidity Biosciences, Araxes Pharma, and Wellspring Biosciences. Cartography, an oncology company developing antibody therapeutics, aims to leverage Wilson's expertise as it advances its pipeline of novel programs targeting tumors more precisely than existing treatments.
Kura Oncology (KURA) reported promising preclinical data for its menin inhibitor ziftomenib in treating gastrointestinal stromal tumors (GIST). The combination of ziftomenib and imatinib demonstrated robust antitumor activity in both imatinib-sensitive and resistant GIST models. The data shows the combination works through a synthetic lethal mechanism, with ziftomenib targeting epigenetic vulnerabilities in GIST tumors. Following FDA clearance of the IND application in August 2024, Kura plans to initiate a proof-of-concept study combining ziftomenib with imatinib in advanced GIST patients after imatinib failure in 1H 2025.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
